Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

Status Active, not recruiting

Clinical Trial Summary

This study is an open-label phase 2 study to evaluate the safety and efficacy of Nivolumab plus Lenvatinib in patients with unresectable anaplastic thyroid cancer.

Clinical Trial Description

This study is an open-label phase 2 study to evaluate the safety and efficacy of Nivolumab plus Lenvatinib in patients with unresectable anaplastic thyroid cancer according to the following steps. Step 1 will evaluate the dose-limiting toxicities (DLT) of Nivolumab plus Lenvatinib in patients with unresectable anaplastic thyroid cancer. Step 2 will evaluate the safety and efficacy of Nivolumab plus Lenvatinib in patients with unresectable anaplastic thyroid cancer. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05696548
Study type	Interventional
Source	National Cancer Center Hospital East
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	July 2, 2019
Completion date	July 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04420754` - Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer	Phase 1
Completed	`NCT02152137` - Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer	Phase 2
Active, not recruiting	`NCT04552769` - Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer	Phase 2
Active, not recruiting	`NCT04400474` - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study	Phase 2
Completed	`NCT02688608` - Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer	Phase 2
Terminated	`NCT00095693` - Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer	Phase 2
Active, not recruiting	`NCT01240590` - A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)	Phase 1/Phase 2
Not yet recruiting	`NCT05819593` - Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
Active, not recruiting	`NCT04579757` - Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT06362694` - Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy	Phase 2
Recruiting	`NCT06374602` - Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer	Phase 2
Withdrawn	`NCT01701349` - Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer	Phase 3
Active, not recruiting	`NCT03085056` - Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer	Early Phase 1
Recruiting	`NCT01774279` - interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
Terminated	`NCT00126568` - Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer	Phase 2
Completed	`NCT02244463` - A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer	Phase 1/Phase 2
Terminated	`NCT00603941` - A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel	Phase 1/Phase 2
Completed	`NCT00280852` - Review of Multimodality Management of Anaplastic Thyroid Cancer	N/A
Recruiting	`NCT04238624` - Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer	Phase 2
Recruiting	`NCT06079333` - NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)	Phase 2